RET gene and tumor

Abstract

Xie Weiwei, Chang Jianhua. RET gene and tumor[J]. Journal of International Oncology, 2015, 42(7): 529-531.

［1］ Ju YS, Lee WC, Shin JY, et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from wholegenome and transcriptome sequencing［J］. Genome Res, 2012, 22（3）: 436-445. ［2］ American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised american thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer［J］. Thyroid, 2009, 19(11): 1167-1214. ［3］ Carr LL, Mankoff DA, Goulart BH, et al. Phase Ⅱ study of daily sunitinib in FDGPETpositive, iodinerefractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation［J］. Clin Cancer Res, 2010, 16(21): 5260-5268. ［4］ Chau NG, Haddad RI. Vandetanib for the treatment of medullary thyroid cancer［J］. Clin Cancer Res, 2013, 19(3): 524-529. ［5］ Pao W, Girard N. New driver mutations in nonsmallcell lung cancer［J］. Lancet Oncol, 2011, 12(2): 175-180. ［6］ Paziewska A, Harris PD, Zwolińska L, et al. Recombination within and between species of the alpha proteobacterium Bartonella infecting rodents［J］. Microb Ecol, 2011, 61(1): 134-145. ［7］ Cai W, Su C, Li X, et al. KIF5BRET fusions in Chinese patients with nonsmall cell lung cancer［J］. Cancer, 2013, 119(8): 1486-1494. ［8］ Kohno T, Ichikawa H, Totoki Y, et al. KIF5BRET fusions in lung adenocarcinoma［J］. Oncol Rep, 2012, 28(4): 1187-1192. ［9］ Wang R, Hu H, Pan Y, et al. RET fusions define a unique molecular and clinicopathologic subtype of nonsmallcell lung cancer［J］. J Clin Oncol, 2012, 30(35): 4352-4359. ［10］ Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer［J］. Nat Med, 2012, 18(3): 378381. ［11］ Pao W, Hutchinson KE. Chipping away at the lung cancer genome［J］. Nat Med, 2012, 18（3）: 349-351. ［12］ Tsuta K, Kohno T, Yoshida Al, et al. RETrearranged nonsmallcell lung carcinoma: a clinicopathological and molecular analysis［J］. Br J Cancer, 2014, 110(6): 1571-1578. ［13］ Dacic S, Luvison A, Evdokimova V, et al. RET rearrangements in lung adenocarcinoma and radiation［J］. J Thorac Oncol, 2014, 9(1): 118-120. ［14］ Marotta V, Guerra A, Sapio MR, et al. RET/PTC rearrangement in benign and malignant thyroid diseases: a clinical standpoint［J］. Eur J Endocrinol, 2011, 165(4): 499-507. ［15］ MinoKenudson M, Chirieac LR, Law K, et al. A novel, highly sensitive antibody allows for the routine detection of ALKrearranged lung adenocarcinomas by standard immunohistochemistry［J］. Clin Cancer Res, 2010, 16(5): 1561-1571. ［16］ Yi ES, Boland JM, Maleszewski JJ, et al. Correlation of IHC and FISH for ALK gene rearrangement in nonsmall cell lung carcinoma: IHC score algorithm for FISH［J］. J Thorac Oncol, 2011, 6(3): 459-465. ［17］ Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies［J］. Nat Med, 2012, 18(3): 382-384. ［18］ Suzuki M, Makinoshima H, Matsumoto S, et al. Identification of a lung adenocarcinoma cell line with CCDC6RET fusion gene and the effect of RET inhibitors in vitro and in vivo［J］. Cancer Sci, 2013, 104(7): 896-903. ［19］ Drilon A, Wang L, Hasanovic A, et al. Response to cabozantinib in patients with RET fusionpositive lung adenocarcinomas［J］. Cancer Discov, 2013, 3(6): 630-635. ［20］ Gautschi O, Zander T, Keller FA, et al. A patient with lung adenocarcinoma and RET fusion treated with vandetanib［J］. J Thorac Oncol, 2013, 8(5): e43-44. ［21］ Morandi A, Martin LA, Gao Q, et al. GDNFRET signaling in ERPositive breast cancers is a key determinant of response and resistance to aromatase inhibitors［J］. Cancer Res, 2013, 73(12): 3783-3795. ［22］ PlazaMenacho I, Morandi A, Robertson D, et al. Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance［J］. Oncogene, 2010, 29(33): 4648-4657. ［23］ Morandi A, PlazaMenacho I, Isacke CM. RET in breast cancer: functional and therapeutic implications［J］. Trends Mol Med, 2011, 17(3): 149-157. ［24］ Gattelli A, Nalvarte I, Boulay A, et al. Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells［J］. EMBO Mol Med, 2013, 5(9): 1335-1350. ［25］ Cavel O, Shomron O, Shabtay A, et al. Endoneurial macrophages induce perineural invasion of pancreatic cancer cells by secretion of GDNF and activation of RET tyrosine kinase receptor［J］. Cancer Res, 2012, 72(22): 5733-5743. ［26］ Wiedmann MW, Mssner J. Safety and efficacy of sunitinib in patients with unresectable pancreatic neuroendocrine tumors［J］. Clin Med Insights Oncol, 2012, 6: 381-393. ［27］ Luo Y, Tsuchiya KD, Ⅱ Park D, et al. RET is a potential tumor suppressor gene in colorectal cancer［J］. Mol Oncol, 2013, 32(16): 2037-2047.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[4]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[5]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[6]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[7]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266.
[8]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan.Progress of ferroptosis-related mechanisms in osteosarcoma[J]. Journal of International Oncology, 2024, 51(5): 308-311.
[9]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong.Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(4): 210-216.
[10]	Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234.
[11]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238.
[12]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao.Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes[J]. Journal of International Oncology, 2024, 51(3): 143-150.
[13]	Qian Xiaotao, Shi Ziyi, Hu Ge.A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(3): 151-156.
[14]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing.Progress of radiotherapy in oligometastatic non-small cell lung cancer[J]. Journal of International Oncology, 2024, 51(3): 170-174.
[15]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180.

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments